❶Warfarin von Thrombophlebitis|- Merck Manuals Consumer Version|Warfarin von Thrombophlebitis Glossar: Medizinische Fachausdrücke von A-Z für den Laien übersetzt|Thrombophilia: Laboratory Support of Diagnosis and Management Warfarin von Thrombophlebitis|Medizinische Fachbegriffe von A-Z von Fachleuten für Laien einfach und verständlich erklärt. Die medizinische Terminologie ist ab sofort leicht verständlich.|Medizinisches Glossar|Search for a Test or Guide]
Individuals Suitable for Testing. Test Selection - Figure. Test Interpretation - Table 4 - Table 5 - Table 6. Almost 2 million Americans succumb annually to a thromboembolic event, 1 with venous thrombosis the third most common cardiovascular disease after ischemic heart disease and stroke. Venous thrombosis affects 1 to 2 in individuals every year and is associated with life-threatening conditions such as pulmonary embolism PE.
Conditions associated with an increased risk of venous thrombosis can be either inherited or acquired Tables 1 and 2. Deficiency of antithrombin, protein C, and protein S may also be acquired. Individuals at high risk for venous thrombosis include those with a personal or family history of thrombosis, inherited coagulation disorders, homocystinuria, paroxysmal nocturnal hemoglobinuria, essential thrombocythemia, polycythemia vera, recurrent spontaneous abortion and stillbirth, and malignancy.
Additional risk factors include surgery, trauma, physical inactivity bed confinement or paralysiswarfarin induced skin necrosis, diabetes, hyperlipidemia, vasculitis, thrombocytopenia, sepsis, congestive heart failure, and use of purified prothrombin complex concentrates.
Other factors that may be associated with increased thrombotic risk include plasminogen deficiency and elevations of plasminogen activator inhibitor-1, lipoprotein aD-dimer, and thrombin-activatable fibrinolysis inhibitor.
The risk of thrombosis increases with the number of defects or risk factors present; ie, individuals with multiple conditions associated with thrombosis are at greater risk than those with only one condition. The identification of thrombotic risk factors and diagnosis of thrombophilia contributes to patient management in multiple ways Table 3. Warfarin von Thrombophlebitis diagnosis is based on personal and family history Warfarin von Thrombophlebitis thrombosis especially during adolescence and young adult yearsclinical manifestations, and laboratory testing.
Clear guidelines how to best manage individuals with a family or personal history of documented risk factors and who have not Warfarin von Thrombophlebitis a thrombotic episode have not been established.
Prophylactic treatment is provided to diagnosed patients when in high-risk situations, eg, surgery, prolonged immobilization, and pregnancy and puerperium. Lifelong prophylactic therapy may be considered for those with recurrent thrombotic episodes, high-risk disorders, or with multiple-risk factors and may Warfarin von Thrombophlebitis plasma transfusions eg, antithrombin concentratesoral anticoagulants, low dose aspirin, and heparin.
Individuals with hyperhomocysteinemia may be treated with vitamin supplementation folic acid, cobalamin, pyridoxine. Individuals Suitable for Testing [ return to contents ] Symptomatic individuals.
High-risk individuals predisposed by surgery, Warfarin von Thrombophlebitis, immobility, pregnancy, oral contraceptives, etc. Test Availability [ return to contents ] Tests available to assist in diagnosis and management of thrombophilia disorders are listed in Appendix 2.
Additionally, Quest Diagnostics offers panels that include multiple tests, thereby simplifying the test http://rk-suedtondern.de/als-zu-krampfadern-an-den-beinen-volksmittel-zu-behandeln.php process.
Refer to the Quest Diagnostics Directory of Services for information on these panels, which are typically named according to the medical condition. Test Selection [ return to contents ] Diagnosis. A venous thrombosis laboratory work-up for high-risk or symptomatic individuals begins with a personal and family history. For example, venous thrombosis in a pediatric patient suggests the likelihood of an inherited disorder; in an individual with SLE, antiphospholipid syndrome more info be considered; and in an Warfarin von Thrombophlebitis individual, malignancy.
Testing for multiple etiologies is recommended since venous thrombosis is a polyfactorial disorder, and presence of multiple etiologies increases the risk for thrombosis. Likewise, if a first thrombotic event occurs after the age of 50, testing for protein C, S, and antithrombin что eine chinesische Patch von Krampfadern kaufen его may be postponed as hypercoagulability due to these disorders usually manifests as thrombosis earlier than the fifth decade.
Trophischen Betrieb von Geschwüren testing directed toward diagnosis of other causes of acquired thrombophilia such as systemic lupus erythematosus, liver disease, nephrotic syndrome, polycythemia vera JAK2 mutationschronic myelogenous leukemia BCR-ABL1 gene rearrangementdiabetes mellitus, Cushing syndrome, etc.
Positive functional assays can be confirmed by genetic testing in some cases or by demonstration of the abnormality in another family member. Such analysis differentiates homozygous and heterozygous states, providing additional prognostic information.
Factor V HR2 allele mutation analysis provides even more prognostic information in factor V Leiden carriers. Homocysteine elevations may be due to an acquired nutritional deficiency vitamin B linkB 6or folate. Acquired causes for antithrombin, protein C, and protein S deficiencies can be ruled out by liver function testing, a disseminated intravascular coagulation screen D-dimer, Warfarin von Thrombophlebitis degradation product, PT, aPTT, fibrinogen, platelet countand a proteinuria test urine albumin.
If all of the aforementioned testing is negative, the patient may have a rare disorder that can be identified by testing for factors IX and XI, lipoprotein a [Lp a ], plasminogen activity functionplasminogen activator inhibitor-1 PAI-1and tissue plasminogen activator TPA ; evaluation for dysfibrinogenemia may also be helpful Figure. Testing for rare disorders is only recommended for individuals with a strong personal and family history of thrombosis and negative first line tests or in whom clinical suspicion is high.
Since all thrombophilia etiologies are not yet known, it is possible for all of these tests to be negative. Since individuals with variations in the CYP2C9 and VKORC1 genes may require lower warfarin doses, http://rk-suedtondern.de/utrozhestan-und-krampfadern.php analysis should be performed to assist in selecting the initial dosage and to prevent over anticoagulating the patient.
Warfarin therapy can be monitored using the prothrombin time test, reported as INR, except in 1 some patients with a strong lupus anticoagulant and 2 patients receiving direct thrombin inhibitors. For these patients, monitoring with Warfarin von Thrombophlebitis factor X is preferred. When injectible anticoagulants are used, patients can be monitored using a Xa inhibition assay.
See Appendix 2 under Heparin and Fondaparinux for Warfarin von Thrombophlebitis details. Additional interpretive information, specific to each test, is Warfarin von Thrombophlebitis below. Increases homocysteine Oral contraceptives. Increases homocysteine Acute phase reaction, inflammation, infection. The cytochrome P enzyme CYP2C9 participates in the metabolism of a number of important drugs, including warfarin. Prolongation is also seen in individuals with lupus anticoagulant.
A decreased ratio of clotting Warfarin von Thrombophlebitis obtained with and without exogenous activated protein C is suggestive of activated protein C APC resistance and Warfarin von Thrombophlebitis risk of deep vein thrombosis. Such cases are also associated with increased venous thrombosis risk.
Decreased levels of antithrombin are associated with an increased risk of both arterial and venous thrombosis and are seen in individuals Warfarin von Thrombophlebitis 3 Varizen was Grad antithrombin deficiency, nephrotic syndrome, colitis, liver disease, active thrombosis, disseminated intravascular coagulation DICthose receiving l -asparaginase therapy or oral contraceptives, and individuals who are pregnant or have undergone surgery.
Warfarin von Thrombophlebitis are also decreased in individuals receiving heparin. Levels in neonates are Warfarin von Thrombophlebitis half of the adult level, which is reached by 6 months of age. Low levels in both the activity and antigen assays indicate type I deficiency, whereas low activity levels in the presence of normal antigen levels indicate type II deficiency dysproteinemia.
Increased levels may be due to oral anticoagulants or heparin cofactor II. Increased levels of C4 Warfarin von Thrombophlebitis protein may cause decreased levels of free protein S, and subsequent increased risk of thrombosis, and are associated with inflammation, pregnancy, Warfarin von Thrombophlebitis mellitus, SLE, AIDS, allograft rejection, estrogen and progesterone administration, and smoking.
IgG antibodies appear read more be more predictive of disease activity, while IgM antibody occurs more often in drug-induced disorders and infectious disease eg, syphilis.
Higher Warfarin von Thrombophlebitis titers are generally correlated with Warfarin von Thrombophlebitis thrombotic risk see Appendix 1.
Elevated levels are associated with myocardial infarction, deep vein thrombosis, pulmonary embolism, DIC and other coagulation disorders, surgery, trauma, sickle cell disease, liver disease, please click for source infection, sepsis, inflammation, malignancy, pregnancy, and hyperfibrinolysis.
When clinical probability is low, a negative result normal level essentially rules out DVT. An uncorrected dRVVT in the mixing study rules out factor deficiencies, specifically those induced by warfarin therapy.
A false-negative dRVVT test may be due to platelet contamination of the plasma. Samples with moderate or severe icterus or lipemia are contraindicated. Such co-inheritance increases the risk of venous thromboembolism 3- to 4-fold when compared with factor V Leiden alone. An individual heterozygous positive for the HR2 allele and negative for factor V Leiden is not at increased risk of thrombosis compared to factor V Leiden alone.
However, homozygosity for factor Warfarin von Thrombophlebitis HR2 is associated with increased risk of thrombosis even in the absence of a factor V Leiden mutation. Factor V Leiden Mutation Analysis. Factor V Warfarin von Thrombophlebitis confers an approximately 7-fold increase in venous thromboembolic events in heterozygous individuals and an fold increase in homozygous subjects. Although this test is highly specific, identification of a mutation may occur in the absence of APCR in rare cases.
A negative result does not rule out Warfarin von Thrombophlebitis or an increased risk of venous thrombosis.
Factor VIII is an acute phase reactant and increased levels are found Warfarin von Thrombophlebitis periods Warfarin von Thrombophlebitis stress, postoperatively, and in inflammatory conditions. Elevated levels are also found at birth and during pregnancy. Increased levels are associated with increased risk for venous thrombosis, 31 whereas decreased levels are associated with hemophilia A.
The presence of soluble fibrin monomer complexes in plasma indicates intravascular thrombin generation. It can be used to support Warfarin von Thrombophlebitis of DIC in the context of other laboratory and clinical findings.
Increased levels are associated with acute phase reactions, pregnancy, and an increased risk of thrombosis. Low fibrinogen activity levels are associated with afibrinogenemia, hypofibrinogenemia, or dysfibrinogenemia which may be associated with thrombophilia in rare instancesas well as with DIC, systemic fibrinolysis, pancreatitis, severe hepatic dysfunction, and l -asparaginase or valproate treatment. Individuals Warfarin von Thrombophlebitis afibrinogenemia or hypofibrinogenemia will have decreased activity and antigen levels.
Individuals with dysfibrinogenemia will typically have decreased activity levels and normal or decreased antigen levels. FDP result from the breakdown of fibrinogen, as well Warfarin von Thrombophlebitis fibrin, by plasmin. Normally, the fibrinolytic process is localized to fibrin, however, during conditions such as DIC, fibrinolysis spreads and becomes systemic.
Persistent elevations indicate that abnormal fibrinolysis and fibrinogenolysis are occurring. Fondaparinux Sodium Xa Inhibition. Fondaparinux is a synthetic pentasaccharide administered subcutaneously and used to prevent or treat thromboembolic conditions.
Measurement is used to monitor therapeutic levels. The therapeutic range is 1. These ranges are applicable to samples collected approximately 3 hours after administration of the drug. LMWH are prepared by the chemical or enzymatic degradation of unfractionated heparin, and http://rk-suedtondern.de/von-krampfadern-geschwollenes-knie.php used in the prevention Warfarin von Thrombophlebitis treatment of thromboembolic conditions.
Measurement of LMWH in plasma is used to monitor therapeutic levels. The therapeutic and prophylactic ranges for samples collected 4 hours after subcutaneous administration are shown in Table 6. Heparin Anti-Xa Unfractionated Heparin.
Unfractionated Warfarin von Thrombophlebitis is used for the prevention and Warfarin von Thrombophlebitis of thromboembolic conditions and measurement is used to monitor therapeutic levels. When administered as an intravenous infusion, the therapeutic range is 0. Levels are increased in the following: When coupled with the factor V Leiden mutation, venous thrombosis risk increases synergistically.
Homocysteine is decreased in pregnancy except in some women carrying a fetus with a neural tube defectindividuals less than 15 years of age, and individuals taking oral contraceptives or hormone replacement therapy.
Human Platelet Antigen 1 HPA-1 Genotype The HPA-1b platelet antigen polymorphism is associated with increased platelet thrombogenecity, neonatal alloimmune thrombocytopenia, and post-transfusion purpura. Lipoprotein a [Lp a ]. Increased levels of Lp a are observed in patients with coronary artery disease, stroke, cerebrovascular and Warfarin von Thrombophlebitis vascular disease, and venous thrombosis.
Substantial increases are secondarily not genetically related observed in nephrotic syndrome and end-stage renal disease. Decreased Lp a levels may be Warfarin von Thrombophlebitis in several rare disorders увидела Ohanyan Varizen Двое